Merck KGaA invests €270 million to create "site of the future"
The investment will fund the construction of a Translational Science Center for its Healthcare business sector, as well as a new Learning Center
Merck KGaA has announced plans to build a new Translational Science Center for its Healthcare business sector and a new Learning Center at its global headquarters in Darmstadt.
This €270 million project is part of the €1 billion investment package the company announced in March 2019.
Kai Beckmann, CEO Electronics and Member of the Executive Board of Merck, said both construction projects, which are expected to be completed by 2025, reflect the strategic importance of of the Darmstadt site, calling it the company's "site of the future".
The new €200 million Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies.
This investment will give rise to an integrated, flexible-use laboratory building covering more than 30,000 m², that includes a lecture hall, in vitro laboratories including a cell bank, as well as a modern and flexible knowledge environment.
The €70 million Learning Center, which is expected to be ready for occupancy in 2024, will comprise seven floors with a surface area of more than 14,000 m2 enabling Merck to house training facilities for all vocational training occupations under one roof.
The building will offer space for laboratories, seminar rooms and workshop, creating sufficient room for 50 employees from the Vocational Training department to prepare the company’s 600 apprentices for the workforce and their assignments within the company. It will also host advanced training at Merck.
Both buildings have been designed to use sustainable materials. By using alternative energy supplies, the buildings will have a lower energy consumption, significantly reducing the carbon footprint compared will conventional methods.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance